PubHawk
J Clin Oncol September 2025 PMID 40454705

Neoadjuvant Osimertinib for Resectable -Mutated Non-Small Cell Lung Cancer.

Jianxing He, Masahiro Tsuboi, Walter Weder, Ke-Neng Chen, Maximilian J Hochmair, Jin-Yuan Shih, Sung Yong Lee, Kang-Yun Lee, Nguyen Viet Nhung, Somcharoen Saeteng, Lunxu Liu, Ligang Xing, Nguyen Hoang Gia, Shuji Murakami, Yongtao Han

Full text PDF Download social card

Mentions

97
Peak: 83 in Jun 2025
across 6 sources since Jun 2025

Extended reach

782,060
potential audience

Total likes

216

Video views

153

Mentions per month

Jun 2025 – Sep 2025

Where it's discussed

  • X / Twitter85 posts
  • News4 articles
  • YouTube2 videos
  • Facebook2 posts
  • Reddit2 posts
  • Blogs2 articles

AI synopsis

What people are saying

The discussions encompass highlights from the study, such as the comparative efficacy of neoadjuvant osimertinib versus chemotherapy in achieving higher major pathologic response rates, with statements like 'major pathologic response 25% compared with 2% for chemotherapy' demonstrating the transformative potential of the findings. The choice of language, such as 'significantly improves treatment outcomes,' contributes to a tone of optimism and urgency around the implications of this research for clinical practice.

AgreementModerate agreement

The majority of discussions express a general support for the findings of the publication, showing slight agreement with the research outcomes.

InterestHigh interest

Several posts reveal a strong curiosity about the efficacy of osimertinib, indicating that the topic is highly relevant to those engaged.

EngagementModerate engagement

While many discussions reference the main findings, the level of deep analysis in the posts remains moderate and varied.

ImpactHigh impact

Participants perceive the publication as having significant influence on treatment approaches for lung cancer, noting improved outcomes.

Abstract in brief

  • Neoadjuvant osimertinib, with or without chemotherapy, shows significant improvement in major pathologic response compared to placebo in patients with non-small cell lung cancer (NSCLC) before surgery.
  • A phase III study involved 358 patients and found that those receiving osimertinib plus chemotherapy had a 26% major pathologic response rate, while those on osimertinib alone had a 25% response rate.
  • The study also noted high event-free survival rates at 12 months and identified adverse events, but no new safety concerns emerged with the treatments.
Read the full abstract

Top posts

Most liked on X and Bluesky
Stephen V Liu, MD
@StephenVLiu · X

NEOADAURA results @JCO_ASCO after #ASCO25 presentation. In pts with resectable #EGFR NSCLC, neoadjuvant osimertinib x 9w led to MPR rate 25%, osi + chemo MPR 26%, placebo + chemo MPR 2%. EFS rates high but most pts received adjuvant osi. https://t.co/kS6HLYAByx

Jun 7, 2025 · 72 likes · 22 shares · 28,431 followers View post →
Masahiro Torasawa, MD. PhD.
@M_Torasawa · X

Hot off the press from #ASCO25!

Jun 2, 2025 · 41 likes · 7 shares · 2,428 followers View post →
Journal of Clinical Oncology
@JCO_ASCO · X

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer. Read full article. https://t.co/7WGW5FItmi

Jun 19, 2025 · 24 likes · 15 shares · 54,542 followers View post →
Masahiro Torasawa, MD. PhD.
@M_Torasawa · X

【NeoADAURA: Neoadjuvant Osimertinib for Resectable EGFR-Mutated NSCLC】

Jun 2, 2025 · 18 likes · 2 shares · 2,428 followers View post →
Bartomeu Massuti
@bmassutis · X

Neo-ADAURA trial presented at #ASCO25 and published at Journal of Clinical Oncology @OncoAlert Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer | Journal of Clinical Oncology https://t.co/f5lSPN4WgO

Jun 2, 2025 · 17 likes · 7 shares · 3,513 followers View post →
Erman Akkus
@Erman_Akkus · X

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer | Journal of Clinical Oncology ⁦@OncoAlert⁩ #ASCO25 https://t.co/zpPWe7BoPK

Jun 2, 2025 · 14 likes · 5 shares · 5,194 followers View post →

All mentions

Cancer_Evolve
@cancer_evolve · X

LUNG: in a study of stage II-IIIB EGFR mutant NSCLC, neoadjuvant EGFR inhibition (osimertinib) delivered major pathologic response 25% compared with 2% for chemotherapy. https://t.co/7krtaQNr3W

Sep 16, 2025 · 369 followers View post →
Isaura R. Penin
@irodriguezpenin · X

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer | Journal of Clinical Oncology https://t.co/zCdET7Dcy2

Sep 9, 2025 · 624 followers View post →
Y. Isomura, MD
@Osler64677120 · X

NACとしてのosime±chemo。Osi使用でMPR 25%ほど。EGFR TKIだけでは治せないんだなあと。 #Osler論文メモ https://t.co/TS4s2TVxJs

Aug 3, 2025 · 3 likes · 659 followers View post →
たろう@病院薬剤師
@taroutarou323 · X

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer - PubMed https://t.co/LeKTe1RJPz

Aug 2, 2025 · 200 followers View post →
Jean Bustamante-Alvarez MD MS
@DoctorJeangoB · X

RT @JCO_ASCO: Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer. Read full article. https://t.co/7WGW5FItmi

Jun 19, 2025 · 15 shares · 542 followers View post →
Mark Mayeda
@MMayedaMD · X

RT @JCO_ASCO: Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer. Read full article. https://t.co/7WGW5FItmi

Jun 19, 2025 · 15 shares · 559 followers View post →
Ali ihsan OLUK
@KasosMete · X

RT @JCO_ASCO: Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer. Read full article. https://t.co/7WGW5FItmi

Jun 19, 2025 · 15 shares · 555 followers View post →
Antonio Torres
@viniciu_antonio · X

RT @JCO_ASCO: Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer. Read full article. https://t.co/7WGW5FItmi

Jun 19, 2025 · 15 shares · 341 followers View post →
sophist93
@sophist93 · X

RT @JCO_ASCO: Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer. Read full article. https://t.co/7WGW5FItmi

Jun 19, 2025 · 15 shares · 12 followers View post →
Rafael Correa Cano MD, MSc.
@Rf_Correa · X

RT @JCO_ASCO: Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer. Read full article. https://t.co/7WGW5FItmi

Jun 19, 2025 · 15 shares · 1,008 followers View post →
Carter Ashbless
@CarterAshbless · X

RT @JCO_ASCO: Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer. Read full article. https://t.co/7WGW5FItmi

Jun 19, 2025 · 15 shares · 268 followers View post →
Andres F. Cardona
@AndresFCardonaZ · X

RT @JCO_ASCO: Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer. Read full article. https://t.co/7WGW5FItmi

Jun 19, 2025 · 15 shares · 8,824 followers View post →
Jason
@jonson_chang123 · X

RT @JCO_ASCO: Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer. Read full article. https://t.co/7WGW5FItmi

Jun 19, 2025 · 15 shares · 84 followers View post →
OncoAlert
@OncoAlert · X

RT @JCO_ASCO: Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer. Read full article. https://t.co/7WGW5FItmi

Jun 19, 2025 · 15 shares · 39,852 followers View post →
Saurabh Parasramka
@SaurabhParas · X

RT @JCO_ASCO: Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer. Read full article. https://t.co/7WGW5FItmi

Jun 19, 2025 · 15 shares · 48 followers View post →
BTOG
@BTOGORG · X

RT @JCO_ASCO: Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer. Read full article. https://t.co/7WGW5FItmi

Jun 19, 2025 · 15 shares · 4,131 followers View post →
denis Moro-Sibilot
@DMSLung · X

RT @JCO_ASCO: Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer. Read full article. https://t.co/7WGW5FItmi

Jun 19, 2025 · 15 shares · 1,270 followers View post →
Journal of Clinical Oncology
@JCO_ASCO · X

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small Cell Lung Cancer. Read full article. https://t.co/7WGW5FItmi

Jun 19, 2025 · 24 likes · 15 shares · 54,542 followers View post →
ZaraBlaze
@ZaraBlaze321 · X

RT @OncLive: @Jani_Chinmay @ChaftJamie @SocietyofMSKCC Full article at : https://t.co/qYuNYOOYjV

Jun 17, 2025 · 2 shares · 286 followers View post →
ALCASE Italia
@ALCASEItalia · X

Lo scopo del lavoro: "L'osimertinib in neoadiuvante migliora la prognosi dei pazienti con cancro al polmone non a piccole cellule (NSCLC) resecabile ed EGFR-mutato, come succede quando lo si usa in adiuvante?..". La risposta è SI! https://t.co/5JZoOnLmlb

Jun 14, 2025 · 320 followers View post →
Charles Ricordel
@C_Ricordel · X

RT @StephenVLiu: NEOADAURA results @JCO_ASCO after #ASCO25 presentation. In pts with resectable #EGFR NSCLC, neoadjuvant osimertinib x 9w l…

Jun 13, 2025 · 22 shares · 575 followers View post →
Jean Bustamante-Alvarez MD MS
@DoctorJeangoB · X

RT @StephenVLiu: NEOADAURA results @JCO_ASCO after #ASCO25 presentation. In pts with resectable #EGFR NSCLC, neoadjuvant osimertinib x 9w l…

Jun 12, 2025 · 22 shares · 542 followers View post →
Fundación ECO
@FundacionECO · X

#Paper | Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell #LungCancer @ASCO @JCO_ASCO Access the entire article here

Jun 12, 2025 · 2 likes · 3,091 followers View post →
STITCHES Medicine - the Best of Medical Research
@STITCHESMed · X

Osimertinib, with or without chemotherapy, significantly improves treatment outcomes for patients with resectable tumors compared to chemotherapy alone. by He J, Tsuboi M (...) Chaft JE et 24 al. in J Clin Oncol https://t.co/HSbybVKzzr #MedX #MedResearch

Jun 11, 2025 · 83 followers View post →
Oncogene Cancer Research
@OncogeneCancer · X

RT @StephenVLiu: NEOADAURA results @JCO_ASCO after #ASCO25 presentation. In pts with resectable #EGFR NSCLC, neoadjuvant osimertinib x 9w l…

Jun 9, 2025 · 22 shares · 955 followers View post →
Allison Chang
@aebchang · X

RT @StephenVLiu: NEOADAURA results @JCO_ASCO after #ASCO25 presentation. In pts with resectable #EGFR NSCLC, neoadjuvant osimertinib x 9w l…

Jun 8, 2025 · 22 shares · 865 followers View post →
Swarnim Thakur
@swarnimthakur87 · X

RT @StephenVLiu: NEOADAURA results @JCO_ASCO after #ASCO25 presentation. In pts with resectable #EGFR NSCLC, neoadjuvant osimertinib x 9w l…

Jun 8, 2025 · 22 shares · 35 followers View post →
Elene Mariamidze
@EMariamidze · X

RT @StephenVLiu: NEOADAURA results @JCO_ASCO after #ASCO25 presentation. In pts with resectable #EGFR NSCLC, neoadjuvant osimertinib x 9w l…

Jun 8, 2025 · 22 shares · 2,464 followers View post →
제빵기는 가라
@dmswn522 · X

RT @StephenVLiu: NEOADAURA results @JCO_ASCO after #ASCO25 presentation. In pts with resectable #EGFR NSCLC, neoadjuvant osimertinib x 9w l…

Jun 7, 2025 · 22 shares · 14 followers View post →
Ali ihsan OLUK
@KasosMete · X

RT @StephenVLiu: NEOADAURA results @JCO_ASCO after #ASCO25 presentation. In pts with resectable #EGFR NSCLC, neoadjuvant osimertinib x 9w l…

Jun 7, 2025 · 22 shares · 555 followers View post →
KIJJAKOM THANASOMBUNSUKH
@KijjakomT · X

RT @StephenVLiu: NEOADAURA results @JCO_ASCO after #ASCO25 presentation. In pts with resectable #EGFR NSCLC, neoadjuvant osimertinib x 9w l…

Jun 7, 2025 · 22 shares · 331 followers View post →
Jennifer Sudahar
@JenniferSudahar · X

RT @StephenVLiu: NEOADAURA results @JCO_ASCO after #ASCO25 presentation. In pts with resectable #EGFR NSCLC, neoadjuvant osimertinib x 9w l…

Jun 7, 2025 · 22 shares · 131 followers View post →
Hugo Arasanz
@ArasanzMd · X

RT @StephenVLiu: NEOADAURA results @JCO_ASCO after #ASCO25 presentation. In pts with resectable #EGFR NSCLC, neoadjuvant osimertinib x 9w l…

Jun 7, 2025 · 22 shares · 70 followers View post →
Ancel Julien, M.D.
@AncelJulienMD · X

RT @StephenVLiu: NEOADAURA results @JCO_ASCO after #ASCO25 presentation. In pts with resectable #EGFR NSCLC, neoadjuvant osimertinib x 9w l…

Jun 7, 2025 · 22 shares · 298 followers View post →
Andres F. Cardona
@AndresFCardonaZ · X

RT @StephenVLiu: NEOADAURA results @JCO_ASCO after #ASCO25 presentation. In pts with resectable #EGFR NSCLC, neoadjuvant osimertinib x 9w l…

Jun 7, 2025 · 22 shares · 8,824 followers View post →
ROSA GARCIA
@DOCRO74 · X

RT @StephenVLiu: NEOADAURA results @JCO_ASCO after #ASCO25 presentation. In pts with resectable #EGFR NSCLC, neoadjuvant osimertinib x 9w l…

Jun 7, 2025 · 22 shares · 124 followers View post →
Saurabh Parasramka
@SaurabhParas · X

RT @StephenVLiu: NEOADAURA results @JCO_ASCO after #ASCO25 presentation. In pts with resectable #EGFR NSCLC, neoadjuvant osimertinib x 9w l…

Jun 7, 2025 · 22 shares · 48 followers View post →
David Reyes Coroceo
@DReyesCoroceo · X

RT @StephenVLiu: NEOADAURA results @JCO_ASCO after #ASCO25 presentation. In pts with resectable #EGFR NSCLC, neoadjuvant osimertinib x 9w l…

Jun 7, 2025 · 22 shares · 20 followers View post →
Diana Bonilla Molina
@Dianabomol · X

RT @StephenVLiu: NEOADAURA results @JCO_ASCO after #ASCO25 presentation. In pts with resectable #EGFR NSCLC, neoadjuvant osimertinib x 9w l…

Jun 7, 2025 · 22 shares · 136 followers View post →
Maria Lucia Reale
@marialuciareale · X

RT @StephenVLiu: NEOADAURA results @JCO_ASCO after #ASCO25 presentation. In pts with resectable #EGFR NSCLC, neoadjuvant osimertinib x 9w l…

Jun 7, 2025 · 22 shares · 400 followers View post →
Mario Mendoza, MD
@Dr_Mario_RMT · X

RT @StephenVLiu: NEOADAURA results @JCO_ASCO after #ASCO25 presentation. In pts with resectable #EGFR NSCLC, neoadjuvant osimertinib x 9w l…

Jun 7, 2025 · 22 shares · 167 followers View post →
monomachi
@monomachi52 · X

RT @StephenVLiu: NEOADAURA results @JCO_ASCO after #ASCO25 presentation. In pts with resectable #EGFR NSCLC, neoadjuvant osimertinib x 9w l…

Jun 7, 2025 · 22 shares · 214 followers View post →
Stephen V Liu, MD
@StephenVLiu · X

NEOADAURA results @JCO_ASCO after #ASCO25 presentation. In pts with resectable #EGFR NSCLC, neoadjuvant osimertinib x 9w led to MPR rate 25%, osi + chemo MPR 26%, placebo + chemo MPR 2%. EFS rates high but most pts received adjuvant osi. https://t.co/kS6HLYAByx

Jun 7, 2025 · 72 likes · 22 shares · 28,431 followers View post →
Mrugal Doshi
@mrugaldoshi · X

https://t.co/ivSMQPUxzZ

Jun 5, 2025 · 55 followers View post →
Mrugal Doshi
@mrugaldoshi · X

RT @JCO_ASCO: Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer. Read full article. https://t.co/CNMoEPLJoX…

Jun 5, 2025 · 4 shares · 55 followers View post →
Isaura R. Penin
@irodriguezpenin · X

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer | Journal of Clinical Oncology https://t.co/WHNZOD0SCV

Jun 5, 2025 · 624 followers View post →
Ali ihsan OLUK
@KasosMete · X

RT @JCO_ASCO: Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer. Read full article. https://t.co/CNMoEPLJoX…

Jun 5, 2025 · 4 shares · 555 followers View post →
Fernando E Mercado MD, FACS
@Dr_Fernando · X

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer | Journal of Clinical Oncology https://t.co/Wins8g98wG

Jun 4, 2025 · 231 followers View post →
Rafael Correa Cano MD, MSc.
@Rf_Correa · X

RT @JCO_ASCO: Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer. Read full article. https://t.co/CNMoEPLJoX…

Jun 4, 2025 · 4 shares · 1,008 followers View post →
shengting Li
@Shengting_Li425 · X

RT @JCO_ASCO: Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer. Read full article. https://t.co/CNMoEPLJoX…

Jun 4, 2025 · 4 shares · 2 followers View post →
Journal of Clinical Oncology
@JCO_ASCO · X

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer. Read full article. https://t.co/CNMoEPLJoX #NSCLC

Jun 4, 2025 · 13 likes · 4 shares · 54,542 followers View post →
Vivek Subbiah, MD
@VivekSubbiah · X

11/Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer @JCO_ASCO #ASCO25 @ASCO https://t.co/jMGUqfXjtQ

Jun 4, 2025 · 2 likes · 38,768 followers View post →
BibliotecaHUVH
@BibliotecaHUVH · X

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer https://t.co/4tg7XmSZLU #hvhebron #onco [Text complet]

Jun 4, 2025 · 2,314 followers View post →
じん
@nijuoti · X

RT @M_Torasawa: Hot off the press from #ASCO25!

Jun 3, 2025 · 7 shares · 1,632 followers View post →
Ancel Julien, M.D.
@AncelJulienMD · X

RT @bmassutis: Neo-ADAURA trial presented at #ASCO25 and published at Journal of Clinical Oncology @OncoAlert Neoadjuvant Osimertinib for R…

Jun 3, 2025 · 7 shares · 298 followers View post →
Andres F. Cardona
@AndresFCardonaZ · X

RT @bmassutis: Neo-ADAURA trial presented at #ASCO25 and published at Journal of Clinical Oncology @OncoAlert Neoadjuvant Osimertinib for R…

Jun 3, 2025 · 7 shares · 8,824 followers View post →
Journal of Clinical Oncology
@JCO_ASCO · X

‼️ #ASCO25 simultaneous publication by Chaft et al:  Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer. Read the full article: https://t.co/I9MWGaTQDH #NSCLC #LungCancer #lcsm https://t.co/myUJ5rlBKd

Jun 3, 2025 · 6 likes · 54,542 followers View post →
ゆう
@yuyakugaku22 · X

RT @M_Torasawa: Hot off the press from #ASCO25!

Jun 3, 2025 · 7 shares · 541 followers View post →
あべ　みゆき
@0641002 · X

RT @M_Torasawa: Hot off the press from #ASCO25!

Jun 3, 2025 · 7 shares · 5,374 followers View post →
Dr. Estela Rodriguez
@Latinamd · X

Jun 2, 2025 · 7,843 followers View post →
Oscar Arrieta
@ogarrieta · X

RT @bmassutis: Neo-ADAURA trial presented at #ASCO25 and published at Journal of Clinical Oncology @OncoAlert Neoadjuvant Osimertinib for R…

Jun 2, 2025 · 7 shares · 3,831 followers View post →
Stefania Colasanti
@Stefani19753108 · X

RT @bmassutis: Neo-ADAURA trial presented at #ASCO25 and published at Journal of Clinical Oncology @OncoAlert Neoadjuvant Osimertinib for R…

Jun 2, 2025 · 7 shares · 815 followers View post →
moc
@akidrmo · X

RT @M_Torasawa: Hot off the press from #ASCO25!

Jun 2, 2025 · 7 shares · 123 followers View post →
Gurubramha
@spandansb · X

RT @M_Torasawa: Hot off the press from #ASCO25!

Jun 2, 2025 · 7 shares · 494 followers View post →
The Innovation | Medicine
@Innov_Medicine · X

RT @M_Torasawa: Hot off the press from #ASCO25!

Jun 2, 2025 · 7 shares · 254,004 followers View post →
Masahiro Torasawa, MD. PhD.
@M_Torasawa · X

Hot off the press from #ASCO25!

Jun 2, 2025 · 41 likes · 7 shares · 2,428 followers View post →
MEDTRACK
@OncoReporte · X

RT @bmassutis: Neo-ADAURA trial presented at #ASCO25 and published at Journal of Clinical Oncology @OncoAlert Neoadjuvant Osimertinib for R…

Jun 2, 2025 · 7 shares · 950 followers View post →
OncoAlert
@OncoAlert · X

RT @bmassutis: Neo-ADAURA trial presented at #ASCO25 and published at Journal of Clinical Oncology @OncoAlert Neoadjuvant Osimertinib for R…

Jun 2, 2025 · 7 shares · 39,852 followers View post →
Gil Morgan, MD
@weoncologists · X

RT @bmassutis: Neo-ADAURA trial presented at #ASCO25 and published at Journal of Clinical Oncology @OncoAlert Neoadjuvant Osimertinib for R…

Jun 2, 2025 · 7 shares · 16,329 followers View post →
よし兄　Yoshi
@aminfield · X

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer | Journal of Clinical Oncology https://t.co/P8fXuDwYRM

Jun 2, 2025 · 57 followers View post →
Bartomeu Massuti
@bmassutis · X

Neo-ADAURA trial presented at #ASCO25 and published at Journal of Clinical Oncology @OncoAlert Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer | Journal of Clinical Oncology https://t.co/f5lSPN4WgO

Jun 2, 2025 · 17 likes · 7 shares · 3,513 followers View post →
Chinmay Jani
@Jani_Chinmay · X

RT @OncLive: @Jani_Chinmay @ChaftJamie @SocietyofMSKCC Full article at : https://t.co/qYuNYOOYjV

Jun 2, 2025 · 2 shares · 1,027 followers View post →
tomisuke
@nextommysuke · X

RT @M_Torasawa: 【NeoADAURA: Neoadjuvant Osimertinib for Resectable EGFR-Mutated NSCLC】

Jun 2, 2025 · 2 shares · 917 followers View post →
MEDTRACK
@OncoReporte · X

RT @Erman_Akkus: Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer | Journal of Clinical Oncology ⁦@OncoAlert…

Jun 2, 2025 · 5 shares · 950 followers View post →
Johan Pluvy
@johanpluvy · X

https://t.co/RyUDbE3sv2

Jun 2, 2025 · 120 followers View post →
Gil Morgan, MD
@weoncologists · X

RT @Erman_Akkus: Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer | Journal of Clinical Oncology ⁦@OncoAlert…

Jun 2, 2025 · 5 shares · 16,329 followers View post →
Stefania Colasanti
@Stefani19753108 · X

RT @Erman_Akkus: Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer | Journal of Clinical Oncology ⁦@OncoAlert…

Jun 2, 2025 · 5 shares · 815 followers View post →
OncoAlert
@OncoAlert · X

RT @Erman_Akkus: Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer | Journal of Clinical Oncology ⁦@OncoAlert…

Jun 2, 2025 · 5 shares · 39,852 followers View post →
Kimberley
@MollyDu127 · X

RT @Erman_Akkus: Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer | Journal of Clinical Oncology ⁦@OncoAlert…

Jun 2, 2025 · 5 shares · 285 followers View post →
OncLive.com
@OncLive · X

@Jani_Chinmay @ChaftJamie @SocietyofMSKCC Full article at : https://t.co/qYuNYOOYjV

Jun 2, 2025 · 1 like · 2 shares · 48,235 followers View post →
Erman Akkus
@Erman_Akkus · X

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer | Journal of Clinical Oncology ⁦@OncoAlert⁩ #ASCO25 https://t.co/zpPWe7BoPK

Jun 2, 2025 · 14 likes · 5 shares · 5,194 followers View post →
MLP Oncología
@MLPOncoData · X

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer https://t.co/QLMUZ5cyCE

Jun 2, 2025 · 1 like · 706 followers View post →
Shinya Yokoe@呼吸器内科/肺癌
@ShinyaYokoe · X

RT @M_Torasawa: 【NeoADAURA: Neoadjuvant Osimertinib for Resectable EGFR-Mutated NSCLC】

Jun 2, 2025 · 2 shares · 17 followers View post →
Masahiro Torasawa, MD. PhD.
@M_Torasawa · X

【NeoADAURA: Neoadjuvant Osimertinib for Resectable EGFR-Mutated NSCLC】

Jun 2, 2025 · 18 likes · 2 shares · 2,428 followers View post →
Dr Akhil Santhosh
@tuttsakhil · X

Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer | @JCO_ASCO https://t.co/PtzVa1yowP

Jun 2, 2025 · 1 like · 884 followers View post →